Navigation Links
Ascension Orthopedics Reaches Milestone With Distribution of 40,000 PyroCarbon Implants
Date:5/3/2011

AUSTIN, Texas, May 3, 2011 /PRNewswire/ -- Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces reaching an industry milestone with the distribution of more than 40,000 PyroCarbon extremity joint replacements worldwide.

Jerome Klawitter, Ph.D., Founder and Chief Science Officer of Ascension Orthopedics, pioneered efforts using PyroCarbon in the manufacture of mechanical heart valves and small joint implants. His collaborative efforts with the Mayo Clinic lead to the founding of Ascension Orthopedics in 1992. Since its introduction of the PyroCarbon MCP Total Joint in 2000, Ascension has been dedicated to building on the company's experience by successfully using PyroCarbon in both hemi and total joint arthroplasty applications. Currently marketed devices include PyroCarbon implants for the finger, thumb, wrist, elbow, shoulder and foot. Ascension has several other PyroCarbon-based extremity products at various stages of development that are not yet commercially available.

"Our commitment to research with PyroCarbon is based on the material's proven durability, enhanced wear resistance and biocompatibility against native bone and cartilage. The elastic modulus of PyroCarbon is very similar to cortical bone and allows a more effective transfer of load from implant to bone, reducing stress shielding and potential bone resorption. PyroCarbon's combination of low surface friction and non-adhesive properties may contribute to the preservation of cartilage observed clinically. The body friendly characteristics of PyroCarbon make it an excellent choice for orthopedic applications," stated Klawitter.

For those interested in learning more about PyroCarbon implants, Ascension offers anatomic workshops lead by surgeon faculty at various locations in both the United States and Europe. These workshops are designed to provide a hands-on environment for the surgeon to become comfortable with products, indications for us
'/>"/>

SOURCE Ascension Orthopedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ascension Orthopedics Hires Key Senior Executives
2. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
3. Ascension Orthopedics Implants First PyroCarbon Shoulder Device in United Kingdom
4. Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System
5. Ascension Orthopedics Announces First Implantations of TITAN™ Modular Shoulder
6. Ascension Orthopedics Announces Implantation of the TITAN™ Modular Total Shoulder
7. Ascension Orthopedics Implants PyroTITAN™ in France
8. Ascension Orthopedics Granted Patent for PyroCarbon Humeral Head Design
9. Ascension Orthopedics Introduces True Modularity With MOVEMENT™ Great Toe System
10. Ascension Orthopedics Announces Market Release of TITAN™ Modular Shoulder Fracture Prosthesis
11. Ascension Orthopedics Announces TITAN™ Modular Shoulder Implantations at Union Memorial Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 ResearchMoz presents this ...  Laparoscopes Market Outlook to 2020. New report, "United States ... on the United States Laparoscopes market . The ... (in units) and average prices (in US dollars) within ... Flexible Tip Video Laparoscopes), Robotic Surgical Systems and Rigid ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new market ... Baby Food Eastern Europe 2014 ... 2014" is a new report by ERC that analyzes ... Eastern Europe , key segments, features & developments, ... examines trends which are currently affecting the industry. Furthermore, ...
(Date:8/27/2014)... 27, 2014 Sihuan Pharmaceutical Holdings Group ... a leading pharmaceutical company with the largest cardio-cerebral ... prescription drug market, today announced the ... subsidiaries (collectively the "Group") for the six months ... Financial HighlightsFor the Six months ended 30 JuneKey ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... in non-responders to previous interferon-based therapy -, ... non- responders, with less frequent ... Annual Meeting of the American Association for the Study of Liver Diseases ... (AASLD) -, ...
... N.C., Nov. 2 /PRNewswire/,-- Fabre-Kramer Pharmaceuticals Inc. (FKP) ... the U.S. Food and Drug Administration (FDA) has ... application for gepirone extended-,release (ER) tablets, submitted for ... The FDA had previously reviewed Phase I through ...
Cached Medicine Technology:Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2
(Date:8/27/2014)... Stoneham, MA (PRWEB) August 27, 2014 ... lockbox payment processing, today announced that it will exhibit ... New York's (IBANYS) 41st annual convention in ... the 9th. , The event will be held at ... number of exciting activities and entertainment options in addition ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... Melbourne, Australia (PRWEB) August 27, 2014 ... by erratic climatic conditions and fluctuations in global supply ... over the past five years. The industry derives a ... manufacturers are subject to global market dynamics, with supply ... as Brazil and India. A strong Australian dollar for ...
(Date:8/27/2014)... Beginning in September, K9 Dog Park will ... interactive, fun way for daycare dogs to learn and compete. ... Park Doggy Daycare clients who bring their dogs into the ... will be able to watch their dogs compete through K9 ... in D.O.G. will win prizes as will the trainers who ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... of Wasatch Indoor Bike Park, Utah’s first indoor mountain bike ... assortment of mountain and park-style bikes in both adult and ... SCOTT Sports, who already operated a distribution warehouse in Ogden, ... to Salt Lake City. , “We are proud to be ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2
... Medicated heart patients might be in danger, study suggests ... boost blood pressure and heart rate and could pose ... Wayne State University researchers. , They found that drinking ... pressure and heart rate in 15 healthy adults, average ...
... controlled, multi-center trial has found that cardiac resynchronization ... during exercise testing, the trial,s primary endpoint, in ... problems that disrupt the heart,s normal rhythm and ... EKG. , The Resynchronization Therapy in Narrow QRS ...
... Nov. 6 ,PharmAthene, Inc. (Amex: PIP ), ... chemical threats, and Medarex, Inc.,(Nasdaq: MEDX ), ... FY 2008 Department of Defense (DoD) appropriations bill ... reimbursement basis to support,ongoing development of Valortim(TM), a ...
... Neurotech Pharmaceuticals, Inc.,a biotechnology company focused on ... diseases, announced today the completion,of enrollment of ... evaluating,NT-501, the Company,s lead product, for the ... (RP) and the dry form of age-related,macular ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three and ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Revenues for the third ... comparable period a year ago. The Company,reported a ...
... - Bioniche Life Sciences,Inc. (TSX: BNC), a research-based, ... Executive,Vice-President, Corporate & Strategic Development, will present at ... in New York City,tomorrow. Mr. Groome will present ... Room of the New York Palace Hotel. ...
Cached Medicine News:Health News:Energy Drinks Could Pose Blood Pressure Risks 2Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 3Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 4Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 5Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 6Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 7Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2
... Size: 3.0 x 5.0 x 100 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... 5.5 x 7.5 x 80 mm. ... II line designed by Harvey A. ... a closed cell sponge which is ... with rounded edges to minimize scleral ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: